The Lancet· Chong-Rui Xu, Yan Zhang, Guinan Lin, Haiyong Wang, Qiming Wang, Dingzhi Huang, Yan Yu, Jin Zhou, Hua Zhong, Lin Wu, Lingxiang Liu, Jianchun Duan, Zhiyi He, Yongzhong Luo, Hongxu Liu, Bi Chen, Xinmin Yu, Feng Xue, Qian Chu, Sanxing Guo, Runxiang Yang, Jia Zhong, Haifeng Liu, Longhua Sun, Xiaorong Dong, Haichuan Su, Peng Zhang, Bin Yang, Sisi He, Yuanyuan Ji, Lixin Wan, Xinghua Han, Jingyu Zhang, Fei Qiu, Lulu Yang, Wei Shi, Yi-Long Wu, HERON-Lung01 Investigators·· 2 小时前精选评分73
中国HERON-Lung01三期中期分析：Ruzaltatug rezetecan较化疗延长EGFR突变晚期NSCLC的PFS
[Articles] Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China
导读
中国随机开放标签三期试验HERON-Lung01中期分析显示，Ruzaltatug rezetecan较化疗显著延长EGFR-TKI治疗后进展的EGFR突变晚期NSCLC的PFS。原文称该药安全性可控，并支持其作为这一人群的潜在治疗选择。
推荐理由
HERON-Lung01中期分析以化疗为对照比较PFS，并同步呈现安全性，便于评估该药在EGFR-TKI耐药人群中的获益与耐受性。
来源：The Lancet · thelancet.com